Genmab — Februar 2019
-
-
Interessant artikel om atezo + dara https://www.medpagetoday.com/reading-room/asco/immunotherapy/78028
-
Og det må være dette forsøg der er udvidet ? https://clinicaltrials.gov/ct2/show/NCT02431208?cond=NCT02431208&rank=1
-
God morgen.
-
Ditto her i Regstrup.
-
Kan ikke huske om denne blev del den anden dag https://www.targetedonc.com/videos/key-takeaway-points-in-phase-iii-alcyone-trial-for-multiple-myeloma
-
Fedt svar fra Lassen https://twitter.com/Genmab/status/1093814035416522752
-
Gary fik problemer med nyrerne pga sygdommen og skal nu starte på dara (som han vist kalder chemo) https://www.youtube.com/watch?v=MhPBTm-mGvw
-
Ny video på websiden om spændende TA-kandidater i næste uge.
Novo Nordisk
Maha Energy
Ambu
Fingerprint Cards
M.fl. -
God morgen.
-
Bob..bob.
-
DnB Markets
We expect focus to be on the 2019 guidance, particularly Darzalex sales and related milestone payments (results due at 17:00 CET on 20 February). It looks set to meet its 2018 guidance and give conservative 2019 guidance of DKK3.5bn–3.9bn in revenue and DKK1.6bn–1.8bn in EBIT. We also expect an update on the MAIA filing. We reiterate our BUY and DKK1,540 target
. Bliver godt med lidt opfølgning i morgen. 
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind